Crystal form of alkynyl pyridine compound and preparation method thereof
Patent Information
- Application Number
- CN202380033449.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-13
- Filing Date
- 2023-06-12
- Publication Date
- 2024-11-22
AI Technical Summary
The mortality rate of invasive fungal diseases is high and the incidence rate is rising. It is difficult for existing technologies to effectively inhibit the cross-linking of mannoproteins in fungal cell walls, affecting their adhesion and cell wall integrity.
Provides C and D crystal forms of alkynylpyridine compounds and a preparation method thereof. Through X-ray powder diffraction patterns of characteristic Cu and Kα radiation and preparation reaction steps, stable crystal forms are prepared for inhibiting Gwt1 activity and interfering with fungi. Mannoprotein cross-linking of cell walls.
This crystal form is effective in treating fungal infections, especially vaginal infections. It has good moisture-absorbing properties and has good drug prospects. It significantly reduces the fungal load and shows excellent medicinal efficacy.
Smart Images

Figure CN119013269A_ABST
Abstract
Description
A crystal form of an alkynylpyridine compound and a preparation method thereof
[0001] The present invention claims the following priority
[0002] Application date: CN202210667399.3; Application number: June 13, 2022. Technical Field
[0003] The present invention relates to a crystal form of an alkynylpyridine compound and a preparation method thereof, and particularly to a crystal form of a compound represented by formula (I) and a preparation method thereof. Background Art
[0004] Invasive fungal disease (IFD) is the most lethal type of fungal infection, with morbidity and mortality rates showing a dramatic upward trend. The fungal cell wall is primarily composed of glucan, chitin, and mannoproteins. Glycosylphosphatidylinositol-anchored proteins (GPI-APs) are anchored to the cell membrane and cell wall, mediating cross-linking between mannoproteins and glucan, and significantly influencing fungal cell wall synthesis, adhesion, and morphological transformation. Gwt1 is a key acetylase in the GPI synthesis process and plays an important role in the formation of GPI precursors. Inhibiting Gwt1 activity blocks GPI-AP synthesis, preventing fungal surface mannoproteins from cross-linking to the cell wall. This, in turn, impairs the ability to adhere to host surfaces and cell wall integrity, exerting an antifungal effect.
[0005] Summary of the Invention
[0006] The present invention provides a crystal form C of a compound of formula (I), characterized in that its Cu, Kα radiation X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 19.9390±0.200°,
[0007] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 15.8368±0.200°, 18.7250±0.200°, 19.9390±0.200°, 21.7115±0.200°, 23.0090±0.200°, 25.6600±0.200°.
[0008] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 15.8368±0.200°, 18.7250±0.200°, 19.9390±0.200°, 20.3246±0.200°, 21.7115±0.200°, 23.0090±0.200°, 25.6600±0.200°.
[0009] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 15.8368±0.200°, 18.7250±0.200°, 19.9390±0.200°, 20.8423±0.200°, 21.7115±0.200°, 22.3334±0.200°, 23.0090±0.200°, 24.0607±0.200°, 25.6600±0.200°, 27.1949±0.200°.
[0010] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 10.7005±0.200°, 12.7114±0.200°, 15.8368±0.200°, 18.7250±0.200°, 19.9390±0. 200°, 20.8423±0.200°, 21.7115±0.200°, 22.3334±0.200°, 23.0090±0.200°, 24.0607±0.200°, 25.6600±0.200°, 27.1949±0.200°, 28.9541±0.200°, 30.3507±0.200°.
[0011] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 15.8368±0.200°, 18.7250±0.200°, 20.3246±0.200°, 21.7115±0.200°, 23.0090±0.200°, 25.6600±0.200°.
[0012] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 12.7114±0.200°, 15.8368±0.200°, 18.7250±0.200°, 19.9390±0.200°, 22.3334±0.200°, 23.0090±0.200°.
[0013] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 12.7114±0.200°, 15.8368±0.200°, 18.7250±0.200°, 19.9390±0.200°, 21.7115±0.200°, 22.3334±0.200°, 23.0090±0.200°, 25.6600±0.200°.
[0014] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, and / or 10.7005±0.200°, and / or 12.7114±0.200°, and / or 15.8368±0.200°, and / or 18.7250±0.200°, and / or 19.9390±0.200°, and / or 20.3246±0.200°, and / or 20.8423±0.200°, and / or 21.2448 ±0.200°, and / or 21.7115±0.200°, and / or 22.3334±0.200°, and / or 23.0090±0.200°, and / or 23.8153±0.200°, and / or 24.0607±0.200°, and / or 25.0930±0.200°, and / or 25.6600±0.200°, and / or 27.1949±0.200°, and / or 28.9541±0.200°, and / or 30.3507±0.200°, and / or 31.1749±0.200°.
[0015] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2θ angles: 4.00°, 7.92°, 10.70°, 12.71°, 15.84°, 18.72°, 19.94°, 20.32°, 20.84°, 21.24°, 21.71°, 22.33°, 23.01°, 23.82°, 24.06°, 25.09°, 25.66°, 27.19°, 28.95°, 30.35°, and 31.17°.
[0016] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2θ angles: 3.9975°, 7.9169°, 10.7005°, 12.7114°, 15.8368°, 18.7250°, 19.9390°, 20.3246°, 20.8423°, 21.2448°, 21.7115°, 22.3334°, 23.0090°, 23.8153°, 24.0607°, 25.0930°, 25.6600°, 27.1949°, 28.9541°, 30.3507°, 31.1749°.
[0017] In some embodiments of the present invention, the XRPD pattern of the above-mentioned Form C is substantially as shown in Figure 1.
[0018] In some embodiments of the present invention, the XRPD pattern analysis data of the above-mentioned Form C are shown in Table 1:
[0019] Table 1. XRPD pattern analysis data of Form C
[0020] In some embodiments of the present invention, the differential scanning calorimetry curve of the above-mentioned crystal form C has an endothermic peak at 199.2±3°C.
[0021] In some embodiments of the present invention, the DSC spectrum of the above-mentioned crystal form C is shown in Figure 2.
[0022] In some embodiments of the present invention, the thermogravimetric analysis curve of the above-mentioned Form C shows a weight loss of 2.28% at 150±3°C.
[0023] In some embodiments of the present invention, the TGA spectrum of the above-mentioned C crystal form is shown in Figure 3.
[0024] The present invention provides a crystal form D of a compound of formula (I), characterized in that its Cu, Kα radiation X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 4.0789±0.200°, 8.1226±0.200°, 14.9322±0.200°, 18.2233±0.200°, 21.4231±0.200°,
[0025] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned D crystal form has characteristic diffraction peaks at the following 2θ angles: 4.0789±0.200°, 7.4609±0.200°, 8.1226±0.200°, 14.9322±0.200°, 18.2233±0.200°, 18.6712±0.200°, 21.4231±0.200°.
[0026] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned D crystal form has characteristic diffraction peaks at the following 2θ angles: 4.0789±0.200°, 7.4609±0.200°, 8.1226±0.200°, 12.1939±0.200°, 14.9322±0.200°, 18.2233±0.200°, 18.6712±0.200°, 21.4231±0.200°, 22.4812±0.200°, 26.2452±0.200°.
[0027] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned D crystal form has characteristic diffraction peaks at the following 2θ angles: 3.75°, 4.08°, 7.46°, 8.12°, 12.19°, 14.93°, 18.22°, 18.67°, 19.38°, 21.42°, 22.48°, and 26.25°.
[0028] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above-mentioned D crystal form has characteristic diffraction peaks at the following 2θ angles: 3.7520°, 4.0789°, 7.4609°, 8.1226°, 12.1939°, 14.9322°, 18.2233°, 18.6712°, 19.3838°, 21.4231°, 22.4812°, and 26.2452°.
[0029] In some embodiments of the present invention, the XRPD pattern of the above-mentioned D crystal form is basically as shown in Figure 4.
[0030] In some embodiments of the present invention, the XRPD pattern analysis data of the above-mentioned D crystal form are shown in Table 2:
[0031] Table 2. XRPD pattern analysis data of Form D
[0032] The present invention also provides a method for preparing compound 1-6, which comprises the following reaction steps:
[0033] in,
[0034] Reagent 4A is selected from an inorganic base;
[0035] Solvent 4B is selected from an acyl solvent or a mixed solvent of an acyl solvent and water;
[0036] Reagent 4C is selected from an inorganic base;
[0037] Reagent 4D is selected from a palladium catalyst;
[0038] Reagent 4E is selected from an organophosphine ligand;
[0039] Solvent 4F is selected from ester solvents.
[0040] In some embodiments of the present invention, the preparation method of compound 1-6, wherein,
[0041] Reagent 4A is selected from potassium fluoride;
[0042] Solvent 4B is selected from DMF or a mixed solvent of DMF and water;
[0043] Reagent 4C is selected from cesium carbonate;
[0044] Reagent 4D is selected from palladium acetate;
[0045] Reagent 4E is selected from Xphos;
[0046] Solvent 4F is selected from isopropyl acetate.
[0047] In some embodiments of the present invention, in the method for preparing compound 1-6, the volume ratio of DMF to water in the mixed solvent of solvent 4B is 5 to 8:1.
[0048] In some embodiments of the present invention, the preparation method of compound 1-6, wherein compound 1-5 is first deprotected using reagent 4A in solvent 4B, and then coupled with compound 1-3 in solvent 4F using reagent 4C, reagent 4D, and reagent 4E.
[0049] In some embodiments of the present invention, the method for preparing compound 1-6, wherein the molar ratio of reagent 4A to compound 1-5 is 4.0 to 6.0:1, the molar ratio of compound 1-3 to compound 1-5 is 0.5 to 1.5:1, the molar ratio of reagent 4C to compound 1-5 is 3 to 5:1, the molar ratio of reagent 4D to compound 1-5 is 0.01 to 0.02:1, and the molar ratio of reagent 4E to compound 1-5 is 0.02 to 0.04:1.
[0050] In some embodiments of the present invention, in the method for preparing compound 1-6, the molar ratio of reagent 4A to compound 1-5 is 4.0 to 6.0:1.
[0051] In some embodiments of the present invention, in the method for preparing compound 1-6, the molar ratio of compound 1-3 to compound 1-5 is 0.5 to 1.5:1.
[0052] In some embodiments of the present invention, in the method for preparing compound 1-6, the molar ratio of reagent 4C to compound 1-5 is 3 to 5:1.
[0053] In some embodiments of the present invention, in the method for preparing compound 1-6, the molar ratio of reagent 4D to compound 1-5 is 0.01 to 0.02:1.
[0054] In some embodiments of the present invention, in the method for preparing compound 1-6, the molar ratio of reagent 4E to compound 1-5 is 0.02 to 0.04:1.
[0055] In some embodiments of the present invention, the method for preparing compound 1-6, wherein the molar ratio of reagent 4A to compound 1-5 is 5.0-5.5:1, the molar ratio of compound 1-3 to compound 1-5 is 0.5-1:1, the molar ratio of reagent 4C to compound 1-5 is 3.5-4.5:1, the molar ratio of reagent 4D to compound 1-5 is 0.01-0.02:1, and the molar ratio of reagent 4E to compound 1-5 is 0.02-0.03:1.
[0056] In some embodiments of the present invention, in the method for preparing compound 1-6, the molar ratio of reagent 4A to compound 1-5 is 5.0 to 5.5:1.
[0057] In some embodiments of the present invention, in the method for preparing compound 1-6, the molar ratio of compound 1-3 to compound 1-5 is 0.5 to 1:1.
[0058] In some embodiments of the present invention, in the method for preparing compound 1-6, the molar ratio of reagent 4C to compound 1-5 is 3.5 to 4.5:1.
[0059] In some embodiments of the present invention, in the method for preparing compound 1-6, the molar ratio of reagent 4D to compound 1-5 is 0.01 to 0.02:1.
[0060] In some embodiments of the present invention, in the method for preparing compound 1-6, the molar ratio of reagent 4E to compound 1-5 is 0.02 to 0.03:1.
[0061] In some embodiments of the present invention, the method for preparing compound 1-6, wherein the temperature range of the reaction system of compound 1-5 with reagent 4A and solvent 4B is controlled to be 10-40°C, and the temperature range of the reaction system with compound 1-3, reagent 4C, reagent 4D, reagent 4E and solvent 4F is controlled to be 60-100°C.
[0062] In some embodiments of the present invention, in the method for preparing compound 1-6, the temperature of the reaction system of compound 1-5, reagent 4A, and solvent 4B is controlled in the range of 10 to 40°C.
[0063] In some embodiments of the present invention, in the method for preparing compound 1-6, the temperature of the reaction system with compound 1-3, reagent 4C, reagent 4D, reagent 4E, and solvent 4F is controlled in the range of 60 to 100°C.
[0064] In some embodiments of the present invention, the method for preparing compound 1-6, wherein the temperature range of the reaction system of compound 1-5 with reagent 4A and solvent 4B is controlled to be 15-25°C, and the temperature range of the reaction system with compound 1-3, reagent 4C, reagent 4D, reagent 4E and solvent 4F is controlled to be 75-85°C.
[0065] In some embodiments of the present invention, in the method for preparing compound 1-6, the temperature of the reaction system of compound 1-5, reagent 4A, and solvent 4B is controlled in the range of 15 to 25°C.
[0066] In some embodiments of the present invention, in the method for preparing compound 1-6, the temperature of the reaction system with compound 1-3, reagent 4C, reagent 4D, reagent 4E, and solvent 4F is controlled in the range of 75 to 85°C.
[0067] In some embodiments of the present invention, the preparation method of compound 1-6, wherein the reaction time of compound 1-5 with reagent 4A and solvent 4B is controlled to be 0.5 to 3 hours, and the reaction time with compound 1-3, reagent 4C, reagent 4D, reagent 4E, and solvent 4F is controlled to be 8 to 24 hours.
[0068] In some embodiments of the present invention, in the method for preparing compound 1-6, the reaction time of compound 1-5 with reagent 4A and solvent 4B is controlled to be 0.5 to 3 hours.
[0069] In some embodiments of the present invention, in the method for preparing compound 1-6, the reaction time with compound 1-3, reagent 4C, reagent 4D, reagent 4E, and solvent 4F is controlled to be 8 to 24 hours.
[0070] In some embodiments of the present invention, the preparation method of compound 1-6, wherein the reaction time of compound 1-5 with reagent 4A and solvent 4B is controlled to be 0.5 to 1.5 hours, and the reaction time with compound 1-3, reagent 4C, reagent 4D, reagent 4E, and solvent 4F is controlled to be 10 to 20 hours.
[0071] In some embodiments of the present invention, in the method for preparing compound 1-6, the reaction time of compound 1-5 with reagent 4A and solvent 4B is controlled to be 0.5 to 1.5 hours.
[0072] In some embodiments of the present invention, in the method for preparing compound 1-6, the reaction time with compound 1-3, reagent 4C, reagent 4D, reagent 4E, and solvent 4F is controlled to be 10 to 20 hours.
[0073] In some embodiments of the present invention, the method for preparing compound 1-6 comprises the following reaction steps:
[0074] in,
[0075] Reagent 3A is selected from a metal catalyst;
[0076] Solvent 3B is selected from nitrile solvents;
[0077] Reagent 3C is selected from trimethylsilyl acetylene;
[0078] Reagent 3D is selected from a palladium catalyst;
[0079] Reagent 3E is selected from an organic base;
[0080] Reagent 4A is selected from an inorganic base;
[0081] Solvent 4B is selected from an acyl solvent or a mixed solvent of an acyl solvent and water;
[0082] Reagent 4C is selected from an inorganic base;
[0083] Reagent 4D is selected from a palladium catalyst;
[0084] Reagent 4E is selected from an organophosphine ligand;
[0085] Solvent 4F is selected from ester solvents.
[0086] In some embodiments of the present invention, the preparation method of compound 1-6, wherein,
[0087] Reagent 3A is selected from cuprous iodide;
[0088] Solvent 3B is selected from acetonitrile;
[0089] Reagent 3C is selected from trimethylsilyl acetylene;
[0090] Reagent 3D is selected from bistriphenylphosphine palladium chloride;
[0091] Reagent 3E is selected from triethylamine;
[0092] Reagent 4A is selected from potassium fluoride;
[0093] Solvent 4B is selected from DMF or a mixed solvent of DMF and water;
[0094] Reagent 4C is selected from cesium carbonate;
[0095] Reagent 4D is selected from palladium acetate;
[0096] Reagent 4E is selected from Xphos;
[0097] Solvent 4F is selected from isopropyl acetate.
[0098] In some embodiments of the present invention, the method for preparing compound 1-6 comprises the following reaction steps:
[0099] in,
[0100] Reagent 1A is selected from terephthalic acid;
[0101] Solvent 1B is selected from DMF;
[0102] Reagent 1C is selected from potassium tert-butoxide;
[0103] Solvent 2A is selected from anhydrous dichloromethane;
[0104] Reagent 2B is selected from thionyl chloride;
[0105] Reagent 3A is selected from cuprous iodide;
[0106] Solvent 3B is selected from acetonitrile;
[0107] Reagent 3C is selected from trimethylsilyl acetylene;
[0108] Reagent 3D is selected from bistriphenylphosphine palladium chloride;
[0109] Reagent 3E is selected from triethylamine;
[0110] Reagent 4A is selected from potassium fluoride;
[0111] Solvent 4B is selected from DMF or a mixed solvent of DMF and water;
[0112] Reagent 4C is selected from cesium carbonate;
[0113] Reagent 4D is selected from palladium acetate;
[0114] Reagent 4E is selected from Xphos;
[0115] Solvent 4F is selected from isopropyl acetate.
[0116] The present invention also provides a method for preparing the compound of formula (I), which comprises the following reaction steps:
[0117] in,
[0118] Reagent 1A is selected from terephthalic acid;
[0119] Solvent 1B is selected from DMF;
[0120] Reagent 1C is selected from potassium tert-butoxide;
[0121] Solvent 2A is selected from anhydrous dichloromethane;
[0122] Reagent 2B is selected from thionyl chloride;
[0123] Reagent 3A is selected from cuprous iodide;
[0124] Solvent 3B is selected from acetonitrile;
[0125] Reagent 3C is selected from trimethylsilyl acetylene;
[0126] Reagent 3D is selected from bistriphenylphosphine palladium chloride;
[0127] Reagent 3E is selected from triethylamine;
[0128] Reagent 4A is selected from potassium fluoride;
[0129] Solvent 4B is selected from DMF or a mixed solvent of DMF and water;
[0130] Reagent 4C is selected from cesium carbonate;
[0131] Reagent 4D is selected from palladium acetate;
[0132] Reagent 4E is selected from Xphos;
[0133] Solvent 4F is selected from isopropyl acetate;
[0134] Solvent 5A is selected from anhydrous tetrahydrofuran;
[0135] Reagent 5B is selected from sodium iodide.
[0136] The present invention also provides the use of crystal form C and crystal form D of the compound of formula (I) in the preparation of drugs for treating deep fungal infections.
[0137] Technical Effects
[0138] The crystal form of the present invention is stable, has good hygroscopicity, and has good drug development prospects. In addition, the crystal form of the present invention can effectively treat vaginal infections.
[0139] Definition and Description
[0140] Unless otherwise indicated, the following terms and phrases used herein are intended to have the following meanings. A particular phrase or term should not be construed as ambiguous or unclear unless specifically defined, but rather should be understood in accordance with its ordinary meaning. When a trade name appears herein, it is intended to refer to the corresponding commercial product or its active ingredient.
[0141] The intermediate compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent replacement methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present invention.
[0142] The chemical reactions of the present invention are carried out in suitable solvents that are compatible with the chemical transformations of the present invention and the reagents and materials required. To obtain the compounds of the present invention, it may sometimes be necessary for those skilled in the art to modify or select synthetic steps or reaction schemes based on existing embodiments.
[0143] It should be noted that during the preparation of drug crystal forms, during the contact between drug molecules and solvent molecules, external conditions and internal factors may cause the solvent molecules to form a co-crystal with the compound molecules and remain in the solid material, which is difficult to avoid, thereby forming solvates, specifically including stoichiometric solvates and non-stoichiometric solvates. All such solvates are included within the scope of the present invention.
[0144] For any given crystalline form, the relative intensity of the diffraction peaks can change due to factors such as the preferred orientation caused by factors such as the crystal morphology, which is well known in the art of crystallography. Where there is a preferred orientation effect, the peak intensity changes, but the position of the diffraction peaks of the crystal form cannot be changed. In addition, for any given crystal form, there may be slight errors in the positions of the peaks, which is also well known in the art of crystallography. For example, due to changes in temperature when analyzing the sample, movement of the sample, or calibration of the instrument, the position of the peak can move, and the measurement error of the 2θ value is sometimes about ± 0.2 degrees. Therefore, it is well known to those skilled in the art that this error should be taken into account when determining each crystalline structure.
[0145] DSC measures the transition temperatures of crystals when they absorb or release heat due to changes in their crystalline structure or melting. For the same crystalline form of the same compound, the error in thermal transition temperatures and melting points in consecutive analyses is typically within about 5°C or 3°C. When we say that a compound has a given DSC peak or melting point, this refers to the DSC peak or melting point ±5°C or ±3°C. DSC provides an auxiliary method for distinguishing different crystalline forms. Different crystalline forms can be identified by their different transition temperature characteristics. It should be noted that for mixtures, their DSC peaks or melting points may vary over a wider range. In addition, since decomposition is associated with the melting process of a substance, the melting temperature is related to the heating rate.
[0146] For the same crystal form, the TGA weight loss temperature may vary due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, the weight loss temperature may have an error of about ±5°C, or about ±3°C.
[0147] Unless otherwise specified, DSC spectra are exothermic upwards.
[0148] All solvents used in the present invention were commercially available and used without further purification.
[0149] The present invention will be described in detail below through examples, which are not intended to limit the present invention in any way.
[0150] The structures of the compounds of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention relates to the absolute configuration of the compounds, the absolute configuration can be confirmed by conventional techniques in the art. For example, single crystal X-ray diffraction (SXRD) is used to collect diffraction intensity data on the cultured single crystal using a Bruker D8venture diffractometer, using CuKα radiation as the light source and scanning mode: After scanning and collecting relevant data, the crystal structure is further analyzed using the direct method (Shelxs97) to confirm the absolute configuration.
[0151] All solvents used in the present invention are commercially available and used without further purification. The present invention uses the following abbreviations: Xphos stands for 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl; DMF stands for N,N-dimethylformamide.
[0152] Compounds are named according to the conventional nomenclature in this field or Software naming, commercially available compounds use supplier catalog names.
[0153] The powder X-ray diffractometer (XRPD) method of the present invention
[0154] Instrument model: PANalytacal X'Pert3 X-ray diffractometer
[0155] Test method: Approximately 10-20 mg of sample was used for XRPD detection.
[0156] The detailed XRPD parameters are as follows:
[0157] Light pipe: Cu, Kα,
[0158] Light tube voltage: 45kV, light tube current: 40mA
[0159] Divergence slit: 1 / 8°
[0160] Scan mode: continuous
[0161] Scanning range: 3-40 degrees
[0162] Scan step: 0.0263 degrees
[0163] Scan time per step: 46.7 seconds
[0164] Test time: ~5 minutes
[0165] Differential Scanning Calorimeter (DSC) method of the present invention
[0166] Instrument model: TA 2500 differential scanning calorimeter
[0167] Test method: Take a sample (~1 mg) and place it in a DSC aluminum pan for testing. Under N2 conditions, heat the sample from 25℃ (room temperature) to 300℃ (or 350℃) at a heating rate of 10℃ / min.
[0168] Thermogravimetric analysis (TGA) method of the present invention
[0169] Instrument model: TA 5500 thermogravimetric analyzer
[0170] Test method: Take a sample (2-5 mg) and place it in a TGA platinum pan for testing. Under N2 conditions, heat the sample from room temperature to 350°C or 20% weight loss at a heating rate of 10°C / min.
[0171] Dynamic Vapor Sorption (DVS) method of the present invention
[0172] Instrument model: SMS DVS Intrinsic
[0173] Test conditions: Take a sample (10-20 mg) and place it in the DVS sample tray for testing.
[0174] The detailed DVS parameters are as follows:
[0175] Temperature: 25℃
[0176] Balance: dm / dt = 0.002% / min (minimum: 10 min, maximum: 180 min)
[0177] Drying: Dry at 0% RH for 120 minutes
[0178] RH (%) range: 0-95%
[0179] RH (%) gradient: 0%-95%
[0180] The classification of moisture absorption evaluation is shown in Table 3:
[0181] Table 3. Hygroscopicity evaluation classification Note: ΔW% indicates the weight gain of the test sample at 25±1℃ and 80±2%RH. BRIEF DESCRIPTION OF THE DRAWINGS
[0182] FIG1 is a Cu-Kα radiation XRPD spectrum of the crystalline form C of the compound of formula (I);
[0183] FIG2 is a DSC spectrum of the crystalline form C of the compound of formula (I);
[0184] FIG3 is a TGA spectrum of the crystalline form C of compound of formula (I);
[0185] FIG4 is a Cu-Kα radiation XRPD spectrum of the crystalline form D of the compound of formula (I);
[0186] Figure 5 is a DVS spectrum of the crystal form C of compound of formula (I). DETAILED DESCRIPTION
[0187] The present invention is described in detail below by way of examples, but is not intended to limit the present invention in any way. While the present invention has been described in detail herein, and specific embodiments thereof have been disclosed, it will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention.
[0188] Example 1: Preparation of Crystalline Form C of Compound (I)
[0189] Step 1:
[0190] Under N2 protection, 2-fluoropyridine (1.0 Kg, 10.3 mol) and p-phenylenediol (2.13 Kg, 15.4 mol) were added to DMF (10.0 L). The solution was cooled to 0°C and potassium tert-butoxide (1.73 Kg, 15.4 mol) was added in batches. After the addition was complete, the reaction system was stirred at 20-35°C for 1 hour. HPLC showed that the reaction was complete. The reaction solution was added to ice water (20 L), washed with n-heptane (10 L × 2), the aqueous phase was extracted with isopropyl acetate (10 L × 2), the organic phase was washed with 10% sodium chloride aqueous solution (10 L), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound 1-2 (1.02 Kg, yield 46%). 1 H NMR(400MHz, CDCl3) δ8.19(dd,J=1.4,5.1Hz,1H),7.61(ddd,J=2.0,6.8,8.5Hz,1H),7.52-7.45(m,2H),7. 43-7.36(m,2H),6.91(ddd,J=0.8,5.0,7.0Hz,1H),6.83(d,J=8.3Hz,1H),5.39(s,2H),4.74-4.69(m,2H).
[0191] Step 2:
[0192] Compound 1-2 (2.0 kg, 9.29 mol) was added to anhydrous dichloromethane (20.0 L), the solution was cooled to 0°C, and dichlorothionyl (1.01 L, 13.93 mol) was slowly added dropwise. After the addition was complete, the reaction system was stirred at 15°C for 1 hour. HPLC showed that the reaction was complete. The reaction solution was directly concentrated under reduced pressure to a solid, slurried with n-heptane (15 L), filtered, and the filter cake was added to ethyl acetate (20 L). The pH was adjusted to 7 with saturated sodium bicarbonate. The organic phase was separated and washed with 10% sodium chloride aqueous solution (10 L), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound 1-3 (1.81 kg, yield 80.9%). 1 H NMR(400MHz, CDCl3)δ8.20(dd,J=1.3,5.0Hz,1H),7.61(ddd,J=1.9,6.9,8.5Hz,1H),7.51-7.47(m,2H),7 .42(d,J=8.3Hz,2H),6.91(ddd,J=0.8,5.1,7.0Hz,1H),6.84(d,J=8.3Hz,1H),5.42(s,2H),4.62(s,2H).
[0193] Step 3:
[0194] 2-Amino-5-iodopyridine (2.0 kg, 90.9 mol) was dissolved in acetonitrile (20 L). Under N2 protection, cuprous iodide (86.6 g, 0.45 mol), trimethylsilylacetylene (1.16 kg, 11.8 mol), triethylamine (2.76 kg, 27.3 mol), and ditriphenylphosphine palladium chloride (63.8 g, 0.091 mol) were added. The reaction mixture was stirred at 20°C for 1 hour. HPLC analysis confirmed the reaction was complete. The reaction solution was directly concentrated under reduced pressure, and the crude product was added to ethyl acetate (20 L), washed with 10% sodium chloride aqueous solution (10 L), and the organic phase was filtered through 200-300 mesh silica gel powder. The filtrate was concentrated to give compound 1-5 (1.59 kg, yield: 92%). 1 H NMR (400MHz, CDCl3) δ=8.22 (d, J=1.5Hz, 1H), 7.51 (dd, J=2.3, 8.5Hz, 1H), 6.43 (d, J=8.5Hz, 1H), 4.71 (s, 2H), 0.24 (s, 9H).
[0195] Step 4:
[0196] Compound 1-5 (1.22 kg, 6.42 mol) was dissolved in DMF (5.0 L), and water (0.77 kg, 42.79 mol) and potassium fluoride (1.98 kg, 34.2 mol) were added at 20 ° C. The mixture was stirred for 1 hour. The reaction solution was added to a mixture of water (15 L) and isopropyl acetate (10 L), filtered, and the aqueous phase was separated and extracted with isopropyl acetate (10.0 L × 2). All isopropyl acetate was combined and washed with 10% sodium chloride aqueous solution (10 L). The organic phase was added to the reactor. Under N2 protection, compound 1-3 (1.0 kg, 4.28 mol), cesium carbonate (1.46 kg, 4.49 mol), Xphos (81.6 g, 0.17 mol) and palladium acetate (19.2 g, 0.09 mol) were added. After the addition was completed, the temperature was raised to 80 ° C and stirred for 16 hours. The reaction was complete as monitored by HPLC, and water (10 L) was added to quench the reaction, filtered, and the aqueous layer was separated and extracted with isopropyl acetate (10 L). The organic phase was washed with 10% brine (10 L), filtered through 200-300 mesh silica gel powder, and concentrated under reduced pressure to a small amount of solvent. Tert-amyl alcohol (3 L) was introduced to displace the isopropyl acetate, filtered, and the filter cake was slurried with n-heptane (5 L), filtered, and the filter cake was dried to obtain compound 1-6 (1.1 Kg, yield: 81.4%). 1H NMR (400MHz, CDCl3) δ = 8.23-8.18 (m, 2H), 7.64-7.56 (m, 1H), 7.51-7.41 (m, 5H), 6.90 (dd, J = 5.6, 6.7Hz, 1H), 6.82 (d, J = 8.3Hz, 1H), 6.45 (d, J = 8.5Hz, 1H), 5.40 (s, 2H), 4.58 (s, 2H), 3.84 (s, 2H).
[0197] Step 5:
[0198] Compound 1-6 (1.1 kg, 3.49 mol) was added to anhydrous tetrahydrofuran (11.0 L), and sodium iodide (0.78 kg, 5.23 mol) and compound 1-7 (1.8 kg, 6.98 mol) were added under N2 protection. The reaction was stirred at 25°C for 16 hours. Add 0.5M sodium carbonate aqueous solution (10L), extract with isopropyl acetate (10L×2), combine the organic phases and wash with 10% sodium chloride aqueous solution (10L), separate the organic phase, add 2M hydrochloric acid aqueous solution (22.0L), stir for 10 minutes to separate the organic phase, continue stirring the aqueous phase for 1 hour, add 4M sodium hydroxide aqueous solution to adjust the pH to 9, wash with isopropyl acetate (10L×2), adjust the pH of the aqueous phase to 4 with 4M hydrochloric acid aqueous solution, a large amount of solid precipitated, stir for 30 minutes and filter, add the filter cake to water (10L), add 4M hydrochloric acid aqueous solution under stirring until dissolved, stir for 1 hour to precipitate a large amount of solid, filter, the filter cake is the hydrochloride of the compound of formula (I). The hydrochloride of the compound of formula (I) was added to water (10 L), and the pH was adjusted to 4 with a 4M aqueous sodium hydroxide solution to precipitate a large amount of solid. The mixture was stirred for 30 minutes and filtered. The filter cake was slurried with pure water (10 L) and filtered. The filter cake was then slurried with a mixture of isopropanol (10 L) and pure water (2.5 L), filtered, and dried to obtain Form C of the compound of formula (I) (700 g, 47.1% yield). 1 H NMR (400 MHz, CD3OD) δ = 8.22-8.10 (m, 2H), 7.83-7.68 (m, 2H), 7.47-7.37 (m, 4H), 7.11-6.96 (m, 2H), 6.88 (d, J = 8.3 Hz, 1H), 5.67 (d, J = 8.3 Hz, 2H), 5.34 (s, 2H), 3.86 (s, 2H). Its XRPD spectrum is shown in Figure 1, its DSC spectrum is shown in Figure 2, and its TGA spectrum is shown in Figure 3.
[0199] Example 2: Preparation of Crystalline Form D of Compound of Formula (I)
[0200] The hydrochloride salt of the compound of formula (I) (15 mg) was added to a 20 mL vial, and the solid was completely dissolved in 0.5 mL of methanol. Acetonitrile was added dropwise to the clear solution while stirring (1000 rpm) until solid precipitated. The precipitated solid was isolated and analyzed by XRPD. The XRPD spectrum is shown in Figure 4.
[0201] Example 3: Hygroscopicity study of the crystalline form of compound C of formula (I)
[0202] Experimental Materials:
[0203] SMS DVS Intrinsic Dynamic Moisture Adsorption Analyzer
[0204] Experimental methods:
[0205] 10-15 mg of the crystalline form C of the compound of formula (I) was placed in a DVS sample tray for testing.
[0206] Experimental results:
[0207] The DVS spectrum of the crystal form C of the compound of formula (I) is shown in FIG5 , ΔW=0.42%.
[0208] Experimental conclusion:
[0209] The weight gain of the crystal form C of the compound of formula (I) at 25° C. and 80% RH was 0.42%, indicating slight hygroscopicity.
[0210] Test Example 1. In vivo efficacy study of the crystal form C of compound of formula (I) in the candidemia model (VVC)
[0211] Experimental animals: Female C3H / NeH mice, 6–8 weeks old, 19–21 g, n = 10;
[0212] Microbial pathogen: Candida albicans ATCC MYA-4788;
[0213] Inoculation level and route: 1.44E+05 CFU / mouse, vaginal instillation infection;
[0214] Treatment: vehicle group; Compound C crystalline form 2, 6, and 20 mpk groups: 1-aminobenzotriazole (ABT) was orally administered 22 h after infection, and the test compound was intraperitoneally injected 24 h before treatment.
[0215] Observation indicators: 96 hours after infection, vaginal tissue homogenates of mice in each group were collected for CFU counting.
[0216] Experimental results: A stable vaginal infection model was established in mice after vaginal instillation of a certain inoculum dose of Candida albicans ATCC MYA-4788. The bacterial load in the vaginal tissue of the Vehicle group was 5.03±0.29 lg. Compared with the Vehicle group, the bacterial load in the vaginal tissue of the crystalline form of Formula (I) C at doses of 20mpk, 6mpk, and 2mpk was reduced by 2.79 lg, 1.58 lg, and 0.68 lg, respectively (P<0.001, P<0.05, P>0.05), and a certain dose-effect relationship was shown. The bactericidal effect of the crystalline form of Formula (I) C at a dose of 20mpk was very significant.
[0217] Experimental conclusion: The crystal form of the present invention can effectively treat vaginal infection, and the crystal form C of compound of formula (I) has excellent pharmaceutical efficacy.
Claims
1. Form C of the compound of formula (I), characterized in that Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 19.939±0.200°, 2. The crystal form C according to claim 1, has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 15.8368±0.200°, 18.7250±0.200°, 19.9390±0.200°, 21.7115±0.200°, 23.0090±0.200°, and 25.6600±0.200°.
3. The crystal form C according to claim 2, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 3.9975±0.200°, 7.9169±0.200°, 15.8368±0.200°, 18.7250±0.200°, 19.9390±0.200°, 20.8423±0.200°, 21.7115±0.200°, 22.3334±0.200°, 23.0090±0.200°, 24.0607±0.200°, 25.6600±0.200°, and 27.1949±0.200°.
4. The crystal form C according to claim 3, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 3.9975°, 7.9169°, 10.7005°, 12.7114°, 15.8368°, 18.7250°, 19.9390°, 20.3246°, 20.8423°, 21.2448°, 21.7115°, 22.3334°, 23.0090°, 23.8153°, 24.0607°, 25.0930°, 25.6600°, 27.1949°, 28.9541°, 30.3507°, and 31.1749°.
5. The crystal form C according to any one of claims 1 to 4, whose XRPD pattern is substantially as shown in Figure 1.
6. The crystal form C according to any one of claims 1 to 4, wherein the differential scanning calorimetry curve thereof has an endothermic peak at 199.2±3°C.
7. The crystal form C according to claim 6, has a DSC spectrum as shown in Figure 2.
8. The crystal form C according to any one of claims 1 to 4, wherein the thermogravimetric analysis curve thereof shows a weight loss of 2.28% at 150±3°C.
9. The crystal form C according to claim 8, whose TGA spectrum is shown in Figure 3.
10. Form D of the compound of formula (I), having an X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2θ angles: 4.0789±0.200°, 8.1226±0.200°, 14.9322±0.200°, 18.2233±0.200°, 21.4231±0.200°, 11. The crystal form D according to claim 10, wherein its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 4.0789±0.200°, 7.4609±0.200°, 8.1226±0.200°, 14.9322±0.200°, 18.2233±0.200°, 18.6712±0.200°, and 21.4231±0.200°.
12. The crystal form D according to claim 11, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 4.0789±0.200°, 7.4609±0.200°, 8.1226±0.200°, 12.1939±0.200°, 14.9322±0.200°, 18.2233±0.200°, 18.6712±0.200°, 21.4231±0.200°, 22.4812±0.200°, and 26.2452±0.200°.
13. The crystal form D according to claim 12, whose XRPD pattern is substantially as shown in Figure 4.
14. A method for preparing compound 1-6, comprising the following reaction steps: in, Reagent 4A is selected from an inorganic base; Solvent 4B is selected from an acyl solvent or a mixed solvent of an acyl solvent and water; Reagent 4C is selected from an inorganic base; Reagent 4D is selected from a palladium catalyst; Reagent 4E is selected from an organophosphine ligand; Solvent 4F is selected from ester solvents.
15. The preparation method according to claim 14, wherein Reagent 4A is selected from potassium fluoride; Solvent 4B is selected from DMF or a mixed solvent of DMF and water; Reagent 4C is selected from cesium carbonate; Reagent 4D is selected from palladium acetate; Reagent 4E is selected from Xphos; Solvent 4F is selected from isopropyl acetate.
16. The preparation method according to claim 15, comprising the following reaction steps: in, Reagent 3A is selected from a metal catalyst; Solvent 3B is selected from nitrile solvents; Reagent 3C is selected from trimethylsilyl acetylene; Reagent 3D is selected from a palladium catalyst; Reagent 3E is selected from an organic base; Reagent 4A is selected from an inorganic base; Solvent 4B is selected from an acyl solvent or a mixed solvent of an acyl solvent and water; Reagent 4C is selected from an inorganic base; Reagent 4D is selected from a palladium catalyst; Reagent 4E is selected from an organophosphine ligand; Solvent 4F is selected from ester solvents.
17. The preparation method according to claim 16, wherein Reagent 3A is selected from cuprous iodide; Solvent 3B is selected from acetonitrile; Reagent 3C is selected from trimethylsilyl acetylene; Reagent 3D is selected from bistriphenylphosphine palladium chloride; Reagent 3E is selected from triethylamine; Reagent 4A is selected from potassium fluoride; Solvent 4B is selected from DMF or a mixed solvent of DMF and water; Reagent 4C is selected from cesium carbonate; Reagent 4D is selected from palladium acetate; Reagent 4E is selected from Xphos; Solvent 4F is selected from isopropyl acetate.
18. The preparation method according to claim 16, comprising the following reaction steps: in, Reagent 1A is selected from terephthalic acid; Solvent 1B is selected from DMF; Reagent 1C is selected from potassium tert-butoxide; Solvent 2A is selected from anhydrous dichloromethane; Reagent 2B is selected from thionyl chloride; Reagent 3A is selected from cuprous iodide; Solvent 3B is selected from acetonitrile; Reagent 3C is selected from trimethylsilyl acetylene; Reagent 3D is selected from bistriphenylphosphine palladium chloride; Reagent 3E is selected from triethylamine; Reagent 4A is selected from potassium fluoride; Solvent 4B is selected from DMF or a mixed solvent of DMF and water; Reagent 4C is selected from cesium carbonate; Reagent 4D is selected from palladium acetate; Reagent 4E is selected from Xphos; Solvent 4F is selected from isopropyl acetate.
19. A method for preparing a compound of formula (I), comprising the following reaction steps: in, Reagent 1A is selected from terephthalic acid; Solvent 1B is selected from DMF; Reagent 1C is selected from potassium tert-butoxide; Solvent 2A is selected from anhydrous dichloromethane; Reagent 2B is selected from thionyl chloride; Reagent 3A is selected from cuprous iodide; Solvent 3B is selected from acetonitrile; Reagent 3C is selected from trimethylsilyl acetylene; Reagent 3D is selected from bistriphenylphosphine palladium chloride; Reagent 3E is selected from triethylamine; Reagent 4A is selected from potassium fluoride; Solvent 4B is selected from DMF or a mixed solvent of DMF and water; Reagent 4C is selected from cesium carbonate; Reagent 4D is selected from palladium acetate; Reagent 4E is selected from Xphos; Solvent 4F is selected from isopropyl acetate; Solvent 5A is selected from anhydrous tetrahydrofuran; Reagent 5B is selected from sodium iodide.
20. Use of the crystal form C according to any one of claims 1 to 9 or the crystal form D according to any one of claims 10 to 13 in the preparation of drugs for treating deep fungal infections.
Citation Information
Cited By
Preparation method of high-purity and high-yield benzyloxypyridine compound
CN119912388A
A method for preparing high-purity and high-yield benzylpyridine compounds
CN119912388B
Analysis method of mutagenic impurities in small molecule fungal inositol acyltransferase 1 inhibitor bulk drug
CN119915948A
